A
$ Value
$0
Shares
28,576
Price
$0
Filed
Aug 29
Insider
Name
Thomas John
Title
—
CIK
0001939103
Roles
Director
Transaction Details
Transaction Date
2025-08-27
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
28,576
Footnotes
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. | The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.
Filing Info
Thomas John's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-02 | GNLX | ▼ | $29K |
| 2025-12-01 | GNLX | ▼ | $50K |
| 2025-08-27 | GNLX | A | $0 |
| 2025-08-27 | GNLX | A | $0 |
| 2025-06-06 | GNLX | G | $0 |
Other Insiders at GNLX (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Yu Yong / Cappello Joseph
SVP, Clinical Development
|
— | $2K | 2026-03-24 |
|
Zindrick Thomas
President and CEO
|
— | $9K | 2026-03-24 |
| Thomas John | — | $29K | 2026-03-02 |
|
Smalling Ralph
Head of Regulatory
|
— | $1K | 2026-03-25 |